Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.77 |
| ▸ | CTSG | P08311 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998748 | 0.92 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3654773 | 0.88 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3708588 | 0.88 | CMA1 (0.81) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL404228 | 0.87 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL31476750 | 0.87 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL23752344 | 0.87 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998105 | 0.87 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL13009082 | 0.87 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999231 | 0.87 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL409986 | 0.86 | CMA1 (0.77) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| EP-1716160-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | EP | disclosed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176769-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885PRSS1 72/4885PRSS2 127/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.